Trinity Biotech plc
TRIB
$0.6792
-$0.0588-7.97%
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -13.32% | 2.74% | -5.79% | -34.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -13.32% | 2.74% | -5.79% | -34.69% |
| Cost of Revenue | -- | -21.06% | -7.67% | 10.10% | -17.45% |
| Gross Profit | -- | 6.79% | 31.10% | -32.12% | -56.83% |
| SG&A Expenses | -- | 13.24% | 59.53% | 41.22% | -10.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 59.01% | -116.38% | -114.24% | 6,788.64% |
| Total Operating Expenses | -- | -7.48% | 9.27% | 14.79% | -12.38% |
| Operating Income | -- | -21.75% | -38.98% | -275.64% | -166.30% |
| Income Before Tax | -- | 14.83% | -10.01% | -71.37% | -363.07% |
| Income Tax Expenses | -- | 68.95% | 94.53% | 71.47% | -764.56% |
| Earnings from Continuing Operations | -- | 14.60% | -13.60% | -77.06% | -354.59% |
| Earnings from Discontinued Operations | -- | 493.40% | 187.46% | 304.84% | 6,334.48% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 41.43% | 11.18% | -40.55% | -308.36% |
| EBIT | -- | -21.75% | -38.98% | -275.64% | -166.30% |
| EBITDA | -- | -31.16% | -47.02% | -450.38% | -150.64% |
| EPS Basic | -- | 50.86% | 31.45% | -2.23% | -186.53% |
| Normalized Basic EPS | -- | -87.81% | -6.98% | -6.98% | -222.50% |
| EPS Diluted | -- | 50.84% | 31.27% | -2.58% | -180.64% |
| Normalized Diluted EPS | -- | -87.81% | -6.98% | -6.98% | -222.50% |
| Average Basic Shares Outstanding | -- | 17.43% | 26.35% | 47.80% | 40.58% |
| Average Diluted Shares Outstanding | -- | 17.43% | 26.34% | 46.43% | 36.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
